Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending October 2011. The report serves as a notification of transactions involving directors and persons discharging managerial responsibility under the Disclosure and Transparency Rule 3.1.4R(1)(a).
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on equity transactions related to a deferred bonus plan.
Material Changes
No material changes to the company's financial position or operations are reported in this filing. The document details an increase in notional interests in Ordinary share ADRs for specific individuals following the re-investment of dividends paid on October 6, 2011, at a price of $42.83 per share.
Guidance, Outlook, and Risks
The filing contains no management commentary, guidance, outlook, or discussion of risks and contingencies. It notes that notional dividends accrued will be paid out based on the percentage of deferred annual bonus holdings that vest after a three-year measurement period.
Key Facts for Investor Verification
- Transaction Type: Notification of ADR acquisitions under the GlaxoSmithKline 2009 Deferred Annual Bonus Plan.
- Participants: Mrs. D P Connelly and Mr. W C Louv.
- Transaction Date: October 12, 2011.
- Share Price: $42.83 per ADR.
- Components: Acquisitions included both personal contributions (dividend re-investment) and company contributions (matching element).